Previous close | 9.60 |
Open | 9.60 |
Bid | 8.70 |
Ask | 12.00 |
Strike | 40.00 |
Expiry date | 2024-09-20 |
Day's range | 9.60 - 9.60 |
Contract range | N/A |
Volume | |
Open interest | 3 |
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Insights into SWTX's robust Q1 performance, strategic initiatives, and forward-looking financial health.
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – – Initiated rolling submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Phase 2b ReNeu trial results accepted for oral presentation at the 2024 ASCO Annual Meeting – STAMFORD, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc